Genetic test guides breast cancer therapy decisions
NCT ID NCT03961880
First seen Nov 01, 2025 · Last updated May 29, 2026 · Updated 24 times
Summary
This study looked at how a genetic test called Oncotype DX affects treatment choices for women with early-stage, hormone-sensitive breast cancer. The test gives a score that predicts the risk of cancer returning and whether chemotherapy would help. Researchers tracked 270 women to see if the test changed their treatment plans and how it related to cancer cells found in the bone marrow.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER FEMALE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department for Women's Health
Tübingen, Baden-Wurttemberg, 72086, Germany
Conditions
Explore the condition pages connected to this study.